Get a preview into the topics being discussed in the following sessions from the speakers who will be presenting:
Plenary Session 1:
Antophospholipid
Syndrome
| Monday 27 November 2017
8:00-10:00 |
Mary-Carmen Amigo, Mexico
Mary-Carmen Amigo | The heart and APS
The heart is a target organ in APS. Valvular lesion is a potential source of cardioembolism to CNS. Heart valve lesion associated to aPL should be considered criteria for APS.
Understand the characteristics, evolution, and importance of the cardiac manifestations in APS.
Read More:
Abreu MM et al. Autoimmunity Rev 2015;14:401-414
|
El corazón en el SAF
Mostrar las características, evolución e importancia del compromiso cardíaco en el SAF.
Lee Más:
Abreu MM et al. Autoimmunity Rev 2015;14:401-414
|
Parallel Session 1:
Systemic Autoimmune Diseases | Monday 27 November 2017
10:40-12:40 |
Gabriela Medina, Mexico
| Metabolic syndrome, autoimmunity and autoimmune rheumatic diseases
Metabolic syndrome (MetS) has increased in the last years throughout the world. Its prevalence is high among autoimmune rheumatic disease patients, leading to cardiovascular disease and consequently to death.
Mechanisms of interaction among MetS, autoimmunity and autoimmune rheumatic disease will be discussed, as well as preventive strategies.
Read more:
Medina G, Gutiérrez-Moreno AL, Vera-Lastra O, Saavedra MA, Jara LJ.Prevalence of metabolic syndrome in primary antiphospholipid syndrome patients. Autoimmun Rev. 2011;10: 214-7.
|
Parallel Session 2: Autoantibody Updates | Monday 27 November 2017
10:40-12:40
|
Jose A Gómez-Puerta, Colombia
| Differences among ACPA positive and ACPA negative Rheumatoid arthritis patients
ACPA antibodies are the hallmark of RA. ACPA antibodies are not only useful markers for diagnosis (in early RA and established RA) but also for prognosis.
More recently, ACPA antibodies have been described as differential marker of clinical response in some non Anti-TNF therapies. Some clinical, histological and radiographic differences among RA ACPA positive or ACPA negative, will be discussed in detail during this session.
Read More:
https://arthritis-research.biomedcentral.com/
|
Parallel Session 4: Systemic Lupus Erythematosus | Tuesday 28 November 2017
10:40-12:40 |
Jose A Gómez-Puerta, Colombia
| Urinary biomarkers in SLE
The knowledge of biomarkers is crucial for practicioners in charge of patiens with autoimmune diseases, including SLE.
Interest on the study of biomarkers in lupus is increasing during last years.
Our aim is to discuss the main urinary biomarkers related with lupus nephritis and to understand their clinical relevance and correlations with different classes of lupus nephritis on kidney biopsies.
|
Plenary Session 5: The Environment in Autoimmunity
| Wednesday 29 November 2017
8:00-10:00
|
Monica Vazquez del Mercado, Mexico
| Obesity, autoimmunity, and autoimmune diseases
Obesity as a worldwide epidemic, it must be considered as an important factor in autoimmune rheumatic diseases beyond an altered metabolic state, as an important contributor able to unbalance the clinical activity of theses diseases.
The session will discuss the role of leptin balance (soluble leptine and leptin receptor), obesity, ACPA and increase in the clinical activity of Rheumatoid Arthritis without comobomidities
Read More:
Vazquez-Del Mercado M. Pubmed |
Obesidad, Autoinmunidad y Enfermedades Autoinmunes
Se discutirá la asociación de los niveles de leptina soluble, receptor soluble de leptina, obesidad, títulos de anti CCP con el incremento de la actividad clinica en Artritis Reumatoide sin comorbidos pre-existentes.
Lee Más:
Vazquez-Del Mercado M. Pubmed |
Plenary Session 6: Advances in Autoimmune Disease Therapy | Wednesday 29 November 2017
10:40-12:40
|
Simone Appenzeller, Brazil
| Role of antibodies and cytokines in CNS manifestations in SLE
NP SLE is frequently observed and is a challenge in clinical practice.
In this session, the role of antibodies and cytokines in NP SLE will be discussed.
Main mimickers of NP SLE will be presented.
|
